CG Oncology, Inc. (CGON)
NASDAQ:CGON
Want to see CGON full AI Analyst Report?
CGON Stock Chart & Stats
$73.43
-$0.55(-1.77%)
At close: 4:00 PM EST
$73.43
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$23.65 - $75.50
Previous Close$30.46
Volume740.02K
Average Volume (3M)907.70K
Market Cap
$4.90B
Enterprise Value$5.47B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$7.58M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Aug 07, 2026EPS Estimate
-0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.34
Shares Outstanding88,202,480
10 Day Avg. Volume942,296
30 Day Avg. Volume907,704
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.08K
Enterprise Value/Gross Profit-2.30K
Enterprise Value/Ebitda-27.62
Forecast
1Y Price Target
$92.50Price Target Upside25.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.72
Revenue Forecast (FY)$11.76M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery large equity and minimal debt provide durable financial flexibility to fund R&D, clinical programs and early commercialization without immediate debt pressure. This reduces refinancing risk over the next 2–6 months and limits leverage-driven constraints on strategic choices.
Experienced Finance LeadershipA proven biotech CFO improves capital planning, investor communication and milestone-based financing strategy as the company approaches commercialization inflection points. PSU grants tied to commercialization align incentives and can reduce executional financing missteps over time.
Top-line Growth MomentumSustained revenue growth, even from a small base, signals improving product/trial traction and supports the pathway to scale. Over 2–6 months this trend can compound into larger revenue contributions if clinical and commercial milestones progress as planned.
Bears Say
High Cash BurnLarge and rising operating cash outflows create a persistent funding need that can force dilutive financings or constrain program spending. Even with strong equity, continued burn raises risk to execution timing and requires careful capital allocation in coming quarters.
Negative Gross Profit And Widening LossesA cost base materially ahead of revenue implies structural unprofitability until clinical success or commercialization scales. Widening losses compress margins and depress returns on equity, making sustained profitability dependent on successful product adoption or partnerships.
Commercial Leadership TurnoverExit of senior commercial leadership and an open CCO role can disrupt launch planning, payer strategy and commercial build-out. Transition risk may delay commercialization readiness or weaken go-to-market execution over the medium term until a permanent CCO is installed.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $23.65 and its highest was $75.50 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $4.90B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 64 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on May 08, 2026. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.556 by -$0.154.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.66.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 88,202,480 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.556. Following the earnings report the stock price went up 0.636%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.50 (25.97% Upside)
$92.50 (25.97% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.13%
12-Months-Change
Fundamentals
Return on Equity
-23.33%
Trailing 12-Months
Asset Growth
55.90%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$92.50
▲(25.97% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
9.93% Insiders
24.93% Mutual Funds
11.43% Other Institutional Investors
39.91% Public Companies and
Individual Investors